Thonzonium (bromide)

CAT: 0804-HY-B1246-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B1246-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A) . Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) [1][2][3].
CAS Number
[553-08-2]
UNSPSC
12352005
Hazard Statement
H302+H312+H332, H315, H318, H335
Target
Bacterial; Proton Pump
Type
Reference compound
Related Pathways
Anti-infection; Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Thonzonium-bromide.html
Purity
99.86
Solubility
DMSO : ≥ 30 mg/mL|H2O : 100 mg/mL (ultrasonic)
Smiles
CCCCCCCCCCCCCCCC[N+](C)(CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2)C.[Br-]
Molecular Formula
C32H55BrN4O
Molecular Weight
591.71
Precautions
H302+H312+H332, H315, H318, H335
References & Citations
[1]Zhu X, et al. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016;104:118-130.|[2]Chan CY, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p) . J Biol Chem. 2012;287 (13) :10236-10250.|[3]Sims KR, et al. Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery. Nanoscale. 2018;11 (1) :219-236.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched

Popular Products